KalVista Pharmaceuticals (KALV) News Today $14.84 +0.32 (+2.20%) As of 02:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALV Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Emerald Advisers LLC Has $10.37 Million Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)July 13 at 6:08 AM | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down on Disappointing EarningsJuly 13 at 2:21 AM | americanbankingnews.comKalVista Pharmaceuticals Provides Operational Update and Fiscal Year ...July 12 at 8:47 PM | seekingalpha.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by Emerald Mutual Fund Advisers TrustJuly 12 at 8:45 AM | marketbeat.comLeerink Partnrs Has Positive Outlook of KALV Q3 EarningsJuly 12 at 3:17 AM | americanbankingnews.comHC Wainwright Has Bullish Forecast for KALV Q4 EarningsJuly 12 at 2:31 AM | americanbankingnews.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down After Earnings MissJuly 11 at 10:15 AM | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 32,979 SharesJuly 11 at 6:14 AM | insidertrades.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Expected to Rise, HC Wainwright Analyst SaysJuly 11 at 2:54 AM | americanbankingnews.comKalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 5.5% Following Analyst UpgradeJuly 11 at 2:23 AM | americanbankingnews.comKalVista Pharmaceuticals: EKTERLY Launch and Financial UpdateJuly 10, 2025 | tipranks.comBenjamin L. Palleiko Sells 32,979 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) StockJuly 10, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial ResultsJuly 10, 2025 | finanznachrichten.deLeerink Partnrs Has Positive Estimate for KALV Q3 EarningsJuly 10, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for KALV EarningsJuly 10, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Issues Earnings Results, Misses Expectations By $0.16 EPSJuly 10, 2025 | marketbeat.comKalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial ResultsJuly 10, 2025 | businesswire.comKalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 5.5% on Analyst UpgradeJuly 9, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Hits New 1-Year High Following Analyst UpgradeJuly 9, 2025 | americanbankingnews.comKalVista's breakthrough drug wins FDA approval after delayJuly 8, 2025 | bizjournals.comFDA approves KalVista’s Ekterly for hereditary angioedemaJuly 8, 2025 | msn.comStocks With Rising Relative Price Strength: KalVista PharmaceuticalsJuly 8, 2025 | msn.comUS FDA approves KalVista's oral swelling disorder drug, shares riseJuly 8, 2025 | msn.comJMP Securities Issues Positive Forecast for KalVista Pharmaceuticals (NASDAQ:KALV) Stock PriceJuly 8, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Price Target Raised to $27.00July 8, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Sets New 52-Week High on Analyst UpgradeJuly 8, 2025 | marketbeat.comLeerink Partners Increases KalVista Pharmaceuticals (NASDAQ:KALV) Price Target to $20.00July 7, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up - Here's What HappenedJuly 7, 2025 | marketbeat.comKalVista stock soars after FDA approves first oral HAE treatmentJuly 7, 2025 | investing.comKalVista Pharmaceuticals Shares Rise on FDA Approval of Hereditary Angioedema DrugJuly 7, 2025 | marketwatch.comUS FDA approves KalVista Pharma's swelling disorder drug, shares riseJuly 7, 2025 | msn.comUS FDA approves KalVista Pharma's swelling disorder drugJuly 7, 2025 | reuters.comKalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary AngioedemaJuly 7, 2025 | businesswire.comKalVista Pharmaceuticals (KALV) Expected to Announce Quarterly Earnings on ThursdayJuly 3, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (KALV) Cash Flow - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | businesswire.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Recommendation of "Buy" from AnalystsJune 30, 2025 | marketbeat.comKalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada - MorningstarJune 27, 2025 | morningstar.comMKalVista Pharmaceuticals, Inc. (KALV) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 3.2% - Should You Sell?June 26, 2025 | marketbeat.comKalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in CanadaJune 26, 2025 | financialpost.comFFDA's Makary sought to reject KalVista’s drug: reportJune 24, 2025 | msn.comKalVista Pharmaceuticals (NASDAQ:KALV) Sees Large Volume Increase - Here's WhyJune 24, 2025 | marketbeat.comHow KalVista Pharma Is Taking On A Rare But Deadly DiseaseJune 20, 2025 | msn.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down - What's Next?June 16, 2025 | marketbeat.comDOGE cuts cause FDA to delay decision on hereditary disease drugJune 16, 2025 | msn.comKalVista Pharmaceuticals Shares Edge Down on FDA Delays for Sebetralstat ApplicationJune 16, 2025 | marketwatch.comFDA Tells Drugmaker ‘Heavy Workload’ to Delay Approval DecisionJune 13, 2025 | bloomberg.comKalVista said FDA will not meet review date for sebetralstatJune 13, 2025 | msn.comKalVista Pharmaceuticals Hit by FDA DelaysJune 13, 2025 | marketwatch.com Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address KALV Media Mentions By Week KALV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KALV News Sentiment▼0.671.01▲Average Medical News Sentiment KALV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KALV Articles This Week▼395▲KALV Articles Average Week Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MTSR News MOR News KYMR News IMVT News ALVO News CRNX News HCM News AMRX News CPRX News BHC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KALV) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
